C. difficile Workshop with Kevin Killeen

Please join us at World Vaccine Congress 2020, in Washington D.C.

April 6, 2020 at 10:00

WORKSHOP D (MORNING ONLY): TACKLE C. difficile

The Centers for Disease Control (CDC) has named C. difficile infections an urgent public health threat and the leading hospital-acquired infection in the U.S. With an enormous human toll, and significant health care costs, there is a clear need to prevent and treat this infection. Join us in this workshop as we hear from experts on their promising approaches to tackle the infection.

Workshop Leader: Kevin Killeen, Chief Scientific Officer, Matrivax

-Vaccine Effort Therapies

-Antibiotics: Merck’s DIFICID® (fidaxomicin)

-Immunotherapy

-Microbiome

-Fecal Microbiota Transplant

Kevin Killeen, Chief Scientific Officer, Matrivax R & D Corp

Mena Boules, Associate Medical Director, Medical Affairs, Gastroenterology, FERRING Pharmaceuticals

Pamela Sears, Vice President Clinical Science, Merck

Elizabeth Hohmann, Infectious Disease, Massachusetts General Hospital

The 2019 CDC list of Antibiotic Resistance Threats in the United States

https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

At Matrivax, we are developing effective vaccines to address three of these concerning threats:

Urgent threat – C. difficile

Serious threat – S. pneumoniae, drug resistant

Serious threat – S. Typhi, drug resistant

Clostridium difficile vaccine development efforts

Dr. Killeen (CEO) will be presenting at Vaccines Research And Development, November 19, 2019, at the Crowne Plaza Boston.

12:10-12:35 Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse. Kevin Killeen, Chief Scientific Officer, Matrivax R&D Corp